

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/030503 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)
C12N 15/00 (2006.01) C07K 16/42 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2022/116860

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

02 September 2022 (02.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/116485

03 September 2021 (03.09.2021) CN

(71) Applicant: LAEKNA THERAPEUTICS SHANGHAI
CO., LTD. [CN/CN]; 5th Floor, 987 Cailun Road,
Zhangjiang, Pudong, Shanghai 201203 (CN).

(72) Inventors: LU, Chris Xiangyang; 15-502, 19 Kaibin
Road, Xuhui District, Shanghai 200232 (CN). GU, Xi-
ang-Ju Justin; 10-1901, Chuanhe Road, Pudong, Shanghai
201210 (CN). ZHANG, Ruipeng; 3-1404, 376 Hangchang
Road, Pudong, Shanghai 201317 (CN). YANG, Mengx-
ue; 15-101, 569 Shangbo Road, Pudong, Shanghai 200123
(CN). ZHANG, Minhua; 22-1202, 99 Dechun Road,
Pudong, Shanghai 201210 (CN). HU, Meijuan; 38-602,
2281 Zhandong Road, Pudong, Shanghai 201203 (CN).

(74) Agent: AFD CHINA INTELLECTUAL PROPERTY
LAW OFFICE; Tower B, 21st Fl., Suite 2108, 38 Xueqing
Road, Haidian, Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTI-ACVR2A ANTIBODIES AND USES THEREOF

(57) Abstract: Anti-ACVR2A antibodies or antigen binding fragment thereof and uses thereof for inhibiting or antagonizing ACVR2A. The antibodies and antigen binding fragments may be used in therapeutic methods for treating ACVR2A or ACVR2A ligands associated diseases or disorders, which are ameliorated or improved by inhibition of ACVR2A.

WO 2023/030503 A1